Compare Crispr Therapeutics AG (CRSP) vs Altria Group Inc (MO) Price & Performance

CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.

The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.

Altria Group (MO) trades at $69.39, up 1.22% today, near the analyst consensus price target of $69.71. The stock shows a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company maintains robust profitability with a 39% net income margin and strong cash flow, though revenue has been slightly declining. Recent earnings have been mixed, with one beat and two misses in the last three quarters. A high dividend yield of approximately 6.6% is supported by 60 consecutive annual increases, but the balance sheet shows negative shareholder equity.

The outlook for MO balances income appeal against structural challenges. The high dividend and bullish analyst consensus (61.5% buy ratings) offer value for income investors, but risks include declining core tobacco sales, regulatory pressures on nicotine products, and a leveraged balance sheet. Earnings growth and smoke-free product adoption are critical for sustained performance.